Featured Research

from universities, journals, and other organizations

New drug shrinks cancer in animals, study shows

Date:
April 9, 2011
Source:
University of Michigan Health System
Summary:
A new study showed in animal studies that new cancer drug compounds they developed shrank tumors, with few side effects.

A study led by researchers at the University of Michigan Comprehensive Cancer Center showed in animal studies that new cancer drug compounds they developed shrank tumors, with few side effects.

Related Articles


The study, done in two mouse models of human cancer, looked at two compounds designed to activate a protein that kills cancer cells. The protein, p53, is inactivated in a significant number of human cancers. In some cases, it is because another protein, MDM2, binds to p53 and blocks its tumor suppressor function. This allows the tumor to grow unchecked. The new compounds block MDM2 from binding to p53, consequently activating p53.

"For the first time, we showed that activation of p53 by our highly potent and optimized MDM2 inhibitors can achieve complete tumor regression in a mouse model of human cancer," says lead study author Shaomeng Wang, Ph.D., Warner-Lambert/Parke-Davis Professor in Medicine and director of the Cancer Drug Discovery Program at the U-M Comprehensive Cancer Center.

Wang presented the study at the American Association for Cancer Research 102nd annual meeting.

Many traditional cancer drugs also activate p53 but they do so by causing DNA damage in both tumor cells and normal cells, causing side effects. These new MDM2 inhibitors activate p53 while avoiding the DNA damage common with other drugs. In this study, which was done in collaboration with Ascenta Therapeutics and sanonfi-aventis, researchers showed that these new drugs shrank tumors without significant side effects.

Because p53 is involved in all types of human cancer, the new drug has potential to be used in multiple types of cancer. Further, the researchers also identified certain markers in tumors that predict which ones will be particularly sensitive to the MDM2 inhibitor, which would allow physicians to target the drug only to patients most likely to benefit.

Additional authors: Wei Sun, Shanghai Yu, Yu-jun Zhao, Sanjeev Kumar, Donna McEachern, Liu Liu, Denzil Bernard, Duxin Sun, Peng Zou, Xiaqin Li, Han Yi, Jeanne Stuckey, Jianting Long and Sami Malek, all from U-M; Dajun Yang, Sanmao Kang, Ming Guo, Brian Wood, Lance Leopold and Mel Sorensen from Ascenta Therapeutics; Cedric Barriere, Isabelle Meaux, Odette Dos-Santos, Jean-Christophe Carry, Pierre-Yves Abecassis, Anne Charlier, Vincent Ferey, Carlos Garcia-Echeverria, Christophe Lengauer and Laurent Debussche from sanofi-aventis

Funding: National Cancer Institute, Ascenta Therapeutics and sanofi-aventis.

Reference: American Association for Cancer Research 102nd Annual Meeting, April 2-6, 2011, Orlando, Fla., Abstract No. LB-204 -- Highly potent and optimized small-molecule inhibitors of MDM2 achieve complete tumor regression in animal models of solid tumors and leukemia


Story Source:

The above story is based on materials provided by University of Michigan Health System. Note: Materials may be edited for content and length.


Cite This Page:

University of Michigan Health System. "New drug shrinks cancer in animals, study shows." ScienceDaily. ScienceDaily, 9 April 2011. <www.sciencedaily.com/releases/2011/04/110406122223.htm>.
University of Michigan Health System. (2011, April 9). New drug shrinks cancer in animals, study shows. ScienceDaily. Retrieved March 31, 2015 from www.sciencedaily.com/releases/2011/04/110406122223.htm
University of Michigan Health System. "New drug shrinks cancer in animals, study shows." ScienceDaily. www.sciencedaily.com/releases/2011/04/110406122223.htm (accessed March 31, 2015).

Share This


More From ScienceDaily



More Health & Medicine News

Tuesday, March 31, 2015

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Solitair Device Aims to Takes Guesswork out of Sun Safety

Solitair Device Aims to Takes Guesswork out of Sun Safety

Reuters - Innovations Video Online (Mar. 31, 2015) — The Solitair device aims to take the confusion out of how much sunlight we should expose our skin to. Small enough to be worn as a tie or hair clip, it monitors the user&apos;s sun exposure by taking into account their skin pigment, location and schedule. Matthew Stock reports. Video provided by Reuters
Powered by NewsLook.com
Soda, Salt and Sugar: The Next Generation of Taxes

Soda, Salt and Sugar: The Next Generation of Taxes

Washington Post (Mar. 30, 2015) — Denisa Livingston, a health advocate for the Dinι Community Advocacy Alliance, and the Post&apos;s Abby Phillip discuss efforts around the country to make unhealthy food choices hurt your wallet as much as your waistline. Video provided by Washington Post
Powered by NewsLook.com
UnitedHealth Buys Catamaran

UnitedHealth Buys Catamaran

Reuters - Business Video Online (Mar. 30, 2015) — The $12.8 billion merger will combine the U.S.&apos; third and fourth largest pharmacy benefit managers. Analysts say smaller PBMs could also merge. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
S. Leone in New Anti-Ebola Lockdown

S. Leone in New Anti-Ebola Lockdown

AFP (Mar. 28, 2015) — Sierra Leone imposed a three-day nationwide lockdown Friday for the second time in six months in a bid to prevent a resurgence of the deadly Ebola virus. Duration: 01:17 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins